CA1208133A - Pulverulent mixture of lipidic constituents and hydrop hobic constituents, methods for obtaining the same hyd rated lipidic lamellar phases and method for producing the same, pharmaceutical or cosmetic compositions com prising hydrated lipidic lamellar phases - Google Patents
Pulverulent mixture of lipidic constituents and hydrop hobic constituents, methods for obtaining the same hyd rated lipidic lamellar phases and method for producing the same, pharmaceutical or cosmetic compositions com prising hydrated lipidic lamellar phasesInfo
- Publication number
- CA1208133A CA1208133A CA000421067A CA421067A CA1208133A CA 1208133 A CA1208133 A CA 1208133A CA 000421067 A CA000421067 A CA 000421067A CA 421067 A CA421067 A CA 421067A CA 1208133 A CA1208133 A CA 1208133A
- Authority
- CA
- Canada
- Prior art keywords
- lipidic
- constituent
- constituents
- amphiphilic
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000470 constituent Substances 0.000 title claims abstract description 105
- 239000000203 mixture Substances 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title claims abstract description 72
- 230000002209 hydrophobic effect Effects 0.000 title claims abstract description 47
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 239000002537 cosmetic Substances 0.000 title claims abstract description 13
- 239000012530 fluid Substances 0.000 claims abstract description 18
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 64
- 239000012736 aqueous medium Substances 0.000 claims description 34
- 239000002904 solvent Substances 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 25
- 239000000725 suspension Substances 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- 238000000889 atomisation Methods 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 238000005538 encapsulation Methods 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 239000008347 soybean phospholipid Substances 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 102000016942 Elastin Human genes 0.000 claims description 6
- 108010014258 Elastin Proteins 0.000 claims description 6
- 229940107161 cholesterol Drugs 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229920002549 elastin Polymers 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- -1 aliphatic fatty acids Chemical class 0.000 claims description 5
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 claims description 4
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 claims description 4
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 claims description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 4
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 claims description 4
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 claims description 4
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 claims description 4
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims description 4
- 229930182558 Sterol Natural products 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 4
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940093541 dicetylphosphate Drugs 0.000 claims description 4
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 claims description 4
- 229940058690 lanosterol Drugs 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 150000003432 sterols Chemical class 0.000 claims description 4
- 235000003702 sterols Nutrition 0.000 claims description 4
- 229960001295 tocopherol Drugs 0.000 claims description 4
- 239000011732 tocopherol Substances 0.000 claims description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 3
- 244000062730 Melissa officinalis Species 0.000 claims description 3
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 3
- 229940032091 stigmasterol Drugs 0.000 claims description 3
- 235000016831 stigmasterol Nutrition 0.000 claims description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 230000007704 transition Effects 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- 241001116389 Aloe Species 0.000 claims description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- ATFFFUXLAJBBDE-FQEVSTJZSA-N N-Stearoyl glutamic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O ATFFFUXLAJBBDE-FQEVSTJZSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 235000011399 aloe vera Nutrition 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229930183167 cerebroside Natural products 0.000 claims description 2
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003720 enoxolone Drugs 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 239000000413 hydrolysate Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000002989 phenols Chemical class 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- AJFWREUFUPEYII-UHFFFAOYSA-N Phosphatidylserin Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC([NH3+])C([O-])=O)OC(=O)CCCCCCCC=CCCCCCCCC AJFWREUFUPEYII-UHFFFAOYSA-N 0.000 claims 1
- YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 239000008344 egg yolk phospholipid Substances 0.000 claims 1
- 150000002191 fatty alcohols Chemical group 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 229940074928 isopropyl myristate Drugs 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 abstract description 34
- 239000000843 powder Substances 0.000 abstract description 25
- 239000002612 dispersion medium Substances 0.000 abstract description 4
- 239000012071 phase Substances 0.000 description 29
- 150000002632 lipids Chemical class 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 239000011780 sodium chloride Substances 0.000 description 12
- 239000006185 dispersion Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229960001701 chloroform Drugs 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 6
- 238000003760 magnetic stirring Methods 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 5
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000193803 Therea Species 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229950005143 sitosterol Drugs 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102000001324 CD59 Antigens Human genes 0.000 description 1
- 108010055167 CD59 Antigens Proteins 0.000 description 1
- 208000031968 Cadaver Diseases 0.000 description 1
- 101100087530 Caenorhabditis elegans rom-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 241001663154 Electron Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 101100305983 Mus musculus Rom1 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000862632 Soja Species 0.000 description 1
- VENIIVIRETXKSV-BQYQJAHWSA-N Ximenynic acid Chemical compound CCCCCC\C=C\C#CCCCCCCCC(O)=O VENIIVIRETXKSV-BQYQJAHWSA-N 0.000 description 1
- VENIIVIRETXKSV-UHFFFAOYSA-N Xionenynic acid Natural products CCCCCCC=CC#CCCCCCCCC(O)=O VENIIVIRETXKSV-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/001—Preparations for care of the lips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8202620 | 1982-02-17 | ||
| FR8202620A FR2521565B1 (fr) | 1982-02-17 | 1982-02-17 | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1208133A true CA1208133A (en) | 1986-07-22 |
Family
ID=9271079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000421067A Expired CA1208133A (en) | 1982-02-17 | 1983-02-07 | Pulverulent mixture of lipidic constituents and hydrop hobic constituents, methods for obtaining the same hyd rated lipidic lamellar phases and method for producing the same, pharmaceutical or cosmetic compositions com prising hydrated lipidic lamellar phases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4508703A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0087993B2 (cg-RX-API-DMAC7.html) |
| JP (1) | JPS5931707A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE20574T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA1208133A (cg-RX-API-DMAC7.html) |
| DE (2) | DE3364299D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK67783A (cg-RX-API-DMAC7.html) |
| ES (1) | ES519878A0 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2521565B1 (cg-RX-API-DMAC7.html) |
| GR (1) | GR77128B (cg-RX-API-DMAC7.html) |
| HK (1) | HK85287A (cg-RX-API-DMAC7.html) |
| IL (1) | IL67939A0 (cg-RX-API-DMAC7.html) |
| SG (1) | SG55887G (cg-RX-API-DMAC7.html) |
Families Citing this family (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2135647A (en) * | 1983-02-15 | 1984-09-05 | Squibb & Sons Inc | Method of preparing liposomes and products produced thereby |
| JPS6058915A (ja) * | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | 薬物含有脂質小胞体製剤 |
| JPS60155109A (ja) * | 1984-01-23 | 1985-08-15 | Terumo Corp | リポソ−ム製剤 |
| US4744989A (en) * | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| GB8613811D0 (en) * | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
| US5141674A (en) * | 1984-03-08 | 1992-08-25 | Phares Pharmaceutical Research N.V. | Methods of preparing pro-liposome dispersions and aerosols |
| US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
| US4891208A (en) * | 1985-04-10 | 1990-01-02 | The Liposome Company, Inc. | Steroidal liposomes |
| GB8423436D0 (en) * | 1984-09-17 | 1984-10-24 | Riker Laboratories Inc | Preparation of liposomes |
| US4830858A (en) * | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
| JPH0676308B2 (ja) * | 1985-06-18 | 1994-09-28 | ポーラ化成工業株式会社 | 皮膚外用剤 |
| US4683092A (en) * | 1985-07-03 | 1987-07-28 | Damon Biotech, Inc. | Capsule loading technique |
| IL79114A (en) * | 1985-08-07 | 1990-09-17 | Allergan Pharma | Method and composition for making liposomes |
| US5230899A (en) * | 1985-08-07 | 1993-07-27 | Smithkline Beecham Corporation | Methods and compositions for making liposomes |
| GB8522964D0 (en) * | 1985-09-17 | 1985-10-23 | Biocompatibles Ltd | Aerosol |
| ATE71540T1 (de) * | 1985-10-21 | 1992-02-15 | Liposome Co Inc | In situ-herstellung und verabreichung von liposomen. |
| FR2591105B1 (fr) | 1985-12-11 | 1989-03-24 | Moet Hennessy Rech | Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide. |
| JPS62152531A (ja) * | 1985-12-26 | 1987-07-07 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製造法 |
| EP0321457A1 (en) * | 1986-01-13 | 1989-06-28 | Research Corporation | Aqueous dispersions of waxes and lipids for pharmaceutical coating |
| US5023108A (en) * | 1986-01-13 | 1991-06-11 | Research Corporation | Aqueous dispersions of waxes and lipids for pharmaceutical coating |
| US4737323A (en) * | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| FR2597345B1 (fr) * | 1986-04-22 | 1990-08-03 | Oreal | Composition cosmetique ou pharmaceutique a base d'une dispersion aqueuse de spherules lipidiques. |
| US4781871A (en) * | 1986-09-18 | 1988-11-01 | Liposome Technology, Inc. | High-concentration liposome processing method |
| EP0285638A4 (en) * | 1986-09-18 | 1989-06-14 | Liposome Technology Inc | METHOD FOR PRODUCING A HIGH DENSITY LIPOSOME. |
| AU599456B2 (en) * | 1986-11-28 | 1990-07-19 | Liposome Company, Inc., The | Phospholipid composition |
| JPS63182029A (ja) * | 1987-01-22 | 1988-07-27 | Agency Of Ind Science & Technol | リポソ−ム |
| NO177774C (no) * | 1987-01-27 | 1995-11-22 | Vestar Inc | Fremgangsmåte for fremstilling av et preparat egnet for tilförsel av en hovedsakelig vannuopplöslig aktiv bestanddel |
| EP0358640B1 (en) * | 1987-02-23 | 1992-09-16 | Vestar, Inc. | Dehydrating vesicule preparations for long-term storage |
| US5089181A (en) * | 1987-02-24 | 1992-02-18 | Vestar, Inc. | Method of dehydrating vesicle preparations for long term storage |
| US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
| NZ223660A (en) * | 1987-03-05 | 1990-11-27 | Liposome Co Inc | Low toxicity drug-lipid complexes; methods of making them; and method of determining their toxicity |
| US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
| IT1223290B (it) * | 1987-07-27 | 1990-09-19 | Indena Spa | Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche |
| US4963362A (en) * | 1987-08-07 | 1990-10-16 | Regents Of The University Of Minnesota | Freeze-dried liposome mixture containing cyclosporin |
| FR2619505B1 (fr) * | 1987-08-20 | 1990-08-31 | Dior Christian Parfums | Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant de la pregnenolone ou un ester de pregnenolone, et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite regeneratrice ou revitalisante, l'incorporant |
| US4950432A (en) * | 1987-10-16 | 1990-08-21 | Board Of Regents, The University Of Texas System | Polyene microlide pre-liposomal powders |
| US5057497A (en) * | 1987-11-10 | 1991-10-15 | Calam & Associates, Inc. | Oral method for the maintenance of healthy gingival tissues using TRF |
| US5290562A (en) * | 1987-11-27 | 1994-03-01 | L V M H Recherche | Compositions and methods employing liposomes including tyrosine or a tyrosine derivative |
| FR2623716B1 (fr) * | 1987-11-27 | 1991-04-05 | Lvmh Rech | Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant de la tyrosine ou un derive de tyrosine et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite pigmentante, l'incorporant |
| US5160669A (en) * | 1988-03-03 | 1992-11-03 | Micro Vesicular Systems, Inc. | Method of making oil filled paucilamellar lipid vesicles |
| US5133965A (en) * | 1988-06-08 | 1992-07-28 | Fountain Pharmaceuticals, Inc. | Dressing material having adsorbed thereon a solvent dilution microcarrier precursor solution |
| US5269979A (en) * | 1988-06-08 | 1993-12-14 | Fountain Pharmaceuticals, Inc. | Method for making solvent dilution microcarriers |
| IL90561A (en) * | 1988-06-08 | 1993-08-18 | Fountain Pharm Inc | Method for making solvent dilution microcarriers |
| FR2633516B1 (fr) * | 1988-06-30 | 1991-03-29 | Clarins | Composition cosmetique pour le traitement des peaux sensibles deshydratees |
| US5096629A (en) * | 1988-08-29 | 1992-03-17 | 501 Nippon Fine Chemical Co., Ltd. | Method for preparing lipid powder for use in preparing liposomes and method for preparing liposomes |
| FR2637182B1 (fr) * | 1988-10-03 | 1992-11-06 | Lvmh Rech | Compositions a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un ecdysteroide, de preference l'ecdysterone, ou l'un de ses derives; et compositions cosmetiques, pharmaceutiques, notamment dermatologiques, de sericulture ou phytosanitaires l'incorporant |
| US5015483A (en) * | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
| US5139803A (en) * | 1989-02-09 | 1992-08-18 | Nabisco, Inc. | Method and liposome composition for the stabilization of oxidizable substances |
| US5077057A (en) * | 1989-04-05 | 1991-12-31 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5549910A (en) * | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5277914A (en) * | 1989-03-31 | 1994-01-11 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| FR2648462B1 (fr) * | 1989-06-15 | 1994-01-28 | Oreal | Procede pour ameliorer l'efficacite therapeutique de corticosteroides liposolubles et composition pour la mise en oeuvre de ce procede |
| US5174988A (en) * | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
| DE69101474T2 (de) * | 1990-07-11 | 1994-07-21 | Quest Int | Stabilisiertes Emulsionssystem. |
| US5246918A (en) * | 1990-07-11 | 1993-09-21 | Unilever Patent Holdings B.V. | Process for preparing perfumed personal products |
| DE69103487T2 (de) * | 1990-07-11 | 1995-02-16 | Quest Int | Parfümierte strukturierte Emulsionen in Körperpflegemitteln. |
| FR2673840A1 (fr) * | 1991-03-14 | 1992-09-18 | Lvmh Rech | Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant de l'oxyacanthine, en particulier destinee a stimuler la pousse des cheveux ou a retarder leur chute. |
| US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| FR2681781A1 (fr) | 1991-09-30 | 1993-04-02 | Oreal | Composition cosmetique anhydre de maquillage comprenant une phase grasse et procede de traitement cosmetique utilisant cette composition. |
| FR2735658B1 (fr) * | 1995-06-21 | 1997-09-12 | Capsulis | Encapsulation de composes a usage alimentaire par des tensioactifs |
| CA2087691A1 (en) * | 1992-01-23 | 1993-07-24 | Peter Critchley | Cosmetic compositon |
| GB9208339D0 (en) * | 1992-04-15 | 1992-06-03 | Unilever Plc | Treatment composition |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| FR2695035A1 (fr) * | 1992-08-25 | 1994-03-04 | Lvmh Rech Gie | Utilisation d'un ecdystéroïde pour la préparation de compositions cosmétiques ou dermatologiques destinées notamment à renforcer la fonction protectrice de la peau, et compositions ainsi obtenues. |
| WO1994012155A1 (en) * | 1992-12-02 | 1994-06-09 | Vestar, Inc. | Antibiotic formulation and process |
| US5958449A (en) * | 1992-12-02 | 1999-09-28 | Nexstar Pharmaceuticals, Inc. | Antibiotic formulation and use for bacterial infections |
| FR2699081B1 (fr) * | 1992-12-11 | 1995-04-07 | Lvmh Rech | Utilisation d'un extrait de Simaba pour l'atténuation des taches pigmentaires cutanées ou pour renforcer la fonction protectrice de la peau, ou pour la préparation d'un milieu de culture de cellules de peau, et composition ainsi obtenue. |
| FR2699080B1 (fr) | 1992-12-11 | 1995-04-07 | Lvmh Rech | Utilisation d'un extrait de Simarouba pour l'atténuation des taches pigmentaires cutanées ou pour renforcer la fonction protectrice de la peau, ou pour la préparation d'un milieu de culture de cellules de peau, et composition ainsi obtenue. |
| US5759571A (en) * | 1993-05-11 | 1998-06-02 | Nexstar Pharmaceuticals, Inc. | Antibiotic formulation and use for drug resistant infections |
| US5554382A (en) * | 1993-05-28 | 1996-09-10 | Aphios Corporation | Methods and apparatus for making liposomes |
| CA2163860A1 (en) * | 1993-06-30 | 1995-01-12 | Chung C. Hsu | Method for preparing liposomes |
| DE4430592A1 (de) * | 1994-08-20 | 1996-02-22 | Max Delbrueck Centrum | Liposomale Zubereitung, ihre Herstellung und ihre Verwendung |
| US5702722A (en) * | 1994-09-30 | 1997-12-30 | Bracco Research S.A. | Liposomes with enhanced entrapment capacity, method and use |
| CH689139A5 (de) * | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| US6147056A (en) * | 1995-06-06 | 2000-11-14 | Trustees Of Boston University | Use of locally applied DNA fragments |
| US7094766B1 (en) | 1995-06-06 | 2006-08-22 | Trustees Of Boston University | Use of locally applied DNA fragments |
| US20030032610A1 (en) * | 1996-06-03 | 2003-02-13 | Gilchrest Barbara A. | Method to inhibit cell growth using oligonucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| IN187860B (cg-RX-API-DMAC7.html) * | 1997-08-27 | 2002-07-06 | Revlon Consumer Prod Corp | |
| US6287590B1 (en) * | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| US5932562A (en) * | 1998-05-26 | 1999-08-03 | Washington University | Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same |
| JP2002527367A (ja) * | 1998-10-14 | 2002-08-27 | コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ナノスケールのステロールおよびステロールエステルの使用 |
| FR2787322B1 (fr) * | 1998-12-18 | 2002-10-18 | Galderma Res & Dev | Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie |
| US6080211A (en) * | 1999-02-19 | 2000-06-27 | Igen, Inc. | Lipid vesicle-based fuel additives and liquid energy sources containing same |
| ES2248082T3 (es) * | 1999-06-25 | 2006-03-16 | Cognis Ip Management Gmbh | Empleo de esteroles y esteres de esterol nanometricos. |
| EP1274410A2 (en) | 2000-03-31 | 2003-01-15 | Trustees Of Boston University | Use of locally applied dna fragments |
| US8658202B2 (en) | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
| US6759058B1 (en) * | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
| BRPI0105509B8 (pt) | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga |
| NZ534377A (en) * | 2002-03-13 | 2008-04-30 | Collagenex Pharm Inc | Water-based topical delivery system consisting of cholesterol, fatty acids water and a phospholipid/ceramide portion. |
| US20050129722A1 (en) * | 2002-03-13 | 2005-06-16 | Collagenex Pharmaceuticals, Inc. | Water-based delivery systems |
| US20060093661A1 (en) | 2002-05-07 | 2006-05-04 | Kapac, Llc | Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs |
| US20030212046A1 (en) * | 2002-05-07 | 2003-11-13 | Kapac, Llc | Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs |
| KR101153459B1 (ko) * | 2002-06-12 | 2012-06-07 | 더 코카콜라 컴파니 | 식물성 스테롤을 함유하는 음료 |
| US7306819B2 (en) * | 2002-06-12 | 2007-12-11 | The Coca-Cola Company | Beverages containing plant sterols |
| US20060269924A1 (en) * | 2003-04-11 | 2006-11-30 | Trustees Of Boston University | Modulation of telomere-initiated cell signaling |
| BRPI0416747A (pt) * | 2003-11-20 | 2007-01-16 | Zomanex Llc | métodos e formulações para o tratamento de condições médicas relacionadas à dihidrotesterona elevada |
| JP2007537758A (ja) * | 2004-05-19 | 2007-12-27 | トラスティーズ オブ ボストン ユニバーシティ | Ｗｒｎ媒介性テロメア開始型細胞シグナル伝達の調節 |
| PT1835922E (pt) * | 2004-12-22 | 2009-07-08 | Merck Serono Sa | Tratamento combinado para esclerose múltipla |
| ES2275443B1 (es) | 2005-11-30 | 2008-06-01 | Italfarmaco, S.A. | Procedimiento de preparacion de liposomas. |
| JP2007261984A (ja) * | 2006-03-28 | 2007-10-11 | Konica Minolta Medical & Graphic Inc | 脂肪酸エステルを有するリポソ−ムおよびその製剤 |
| US8007790B2 (en) | 2006-04-03 | 2011-08-30 | Stowers Institute For Medical Research | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases |
| AU2007357448B2 (en) * | 2006-09-18 | 2012-09-06 | Compugen Ltd | Bioactive peptides and method of using same |
| US20080124387A1 (en) | 2006-11-27 | 2008-05-29 | Kapac, Llc | Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients |
| GB0623838D0 (en) * | 2006-11-29 | 2007-01-10 | Malvern Cosmeceutics Ltd | Novel compositions |
| US20080207711A1 (en) * | 2007-02-28 | 2008-08-28 | Rong Li | Method for treating an ID2-related disorder |
| JP5355561B2 (ja) | 2007-07-12 | 2013-11-27 | コンピュゲン エルティーディー． | 生物活性ペプチドおよびその使用方法 |
| US20090088393A1 (en) * | 2007-09-28 | 2009-04-02 | Zomanex, Llc | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
| SG185311A1 (en) | 2007-10-16 | 2012-11-29 | Repros Therapeutics Inc | Trans-clomiphene for metabolic syndrome |
| US8101606B2 (en) * | 2007-11-12 | 2012-01-24 | Washington University | Neurofibromin pathway modulators |
| EP3561494B1 (en) | 2007-12-06 | 2022-03-02 | Genalyte, Inc. | METHOD FOR IDENTIFYING A SEQUENCE OF NUCLEOTIDES IN AN UNKNOWN SPECIES OF NUCLEIC ACID 
AND DEVICE FOR CARRYING OUT THE METHOD |
| TWI539953B (zh) | 2008-04-28 | 2016-07-01 | 瑞波若斯治療學公司 | 用於治療乳癌之組成物和方法 |
| TWI477276B (zh) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| EP2347247B1 (en) | 2008-10-27 | 2019-06-26 | Genalyte, Inc. | Biosensors based on optical probing and sensing |
| US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
| EP2480208A1 (en) | 2009-09-23 | 2012-08-01 | Indu Javeri | Methods for the preparation of liposomes |
| JP5894143B2 (ja) | 2010-03-22 | 2016-03-23 | リプロス セラピューティクス インコーポレイテッド | 抗黄体ホルモンの無毒送達のための組成物および方法 |
| CN103002878B (zh) | 2010-04-09 | 2015-07-01 | 帕西拉制药有限公司 | 用于配制大直径合成膜囊泡的方法 |
| EP2635710B1 (en) | 2010-11-05 | 2017-08-09 | Genalyte, Inc. | Optical analyte detection systems and methods of use |
| UA113283C2 (xx) | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| EP2672958A1 (en) | 2011-02-08 | 2013-12-18 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| EP3907506A1 (en) | 2012-03-12 | 2021-11-10 | The Board of Trustees of the University of Illinois | Optical analyte detection systems with magnetic enhancement and methods of their use |
| JP6341910B2 (ja) | 2012-05-31 | 2018-06-13 | レプロス セラピューティクス インコーポレイティド | 抗プロゲスチンの経膣送達用製剤およびその送達方法 |
| AU2013338305B2 (en) | 2012-11-02 | 2018-06-07 | Allergan pharmaceuticals International Ltd. | Methods and compositions for treating progesterone-dependent conditions |
| PL3186281T3 (pl) | 2014-08-28 | 2019-10-31 | Halozyme Inc | Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej |
| EP3247333B1 (en) | 2015-01-20 | 2021-07-21 | Tetraderm Group LLC | Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration |
| MX381655B (es) | 2015-05-04 | 2025-03-13 | Versantis AG | Metodo para preparar vesiculas con gradiente de ph de transmembrana. |
| EP3124609A1 (en) | 2015-07-29 | 2017-02-01 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Therapeutics oligonucleotides |
| ES2781459T3 (es) | 2015-07-29 | 2020-09-02 | Ifom Fondazione St Firc Di Oncologia Molecolare | Oligonucleótidos terapéuticos |
| WO2017027622A1 (en) | 2015-08-11 | 2017-02-16 | Scintillon Institute For Biomedical And Bioenergy Research | Optical analyses of particles and vesicles |
| ITUA20161994A1 (it) | 2016-03-24 | 2017-09-24 | Azienda Ospedaliera Univ Senese | Uso degli inibitori ddx3 come agenti anti-iperproliferativi |
| JP7019201B2 (ja) | 2016-08-02 | 2022-02-15 | キュリアールエックス インコーポレーテッド | リポソームの調製方法 |
| EP3573619A4 (en) | 2017-01-27 | 2020-10-28 | SignalRX Pharmaceuticals, Inc. | THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS |
| EP3827006A4 (en) | 2018-07-23 | 2022-04-06 | Signalrx Pharmaceuticals, Inc. | SINGLE MOLECULE COMPOUNDS PROVIDING MULTI-TARGET INHIBITION OF BTK AND OTHER PROTEINS AND METHODS OF USING THEM |
| US20220090083A1 (en) | 2018-09-12 | 2022-03-24 | The Broad Institute, Inc. | Targeting egln1 in cancer |
| EP4050002A1 (en) | 2021-02-26 | 2022-08-31 | First Health Pharmaceuticals B.V. | Anti-proliferative agents |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL238195A (cg-RX-API-DMAC7.html) * | 1959-04-15 | |||
| US3499962A (en) * | 1967-08-24 | 1970-03-10 | Nat Starch Chem Corp | Encapsulation of water insoluble materials |
| CA1047924A (en) * | 1973-10-30 | 1979-02-06 | Kyowa Hakko Kogyo Co. | Powdered emulsion product and method of production |
| FR2315991A1 (fr) * | 1975-06-30 | 1977-01-28 | Oreal | Procede de fabrication de dispersions aqueuses de spherules lipidiques et nouvelles compositions correspondantes |
| IN147123B (cg-RX-API-DMAC7.html) * | 1976-10-19 | 1979-11-17 | Standard Oil Co Ohio | |
| US4235792A (en) * | 1977-04-14 | 1980-11-25 | The Governing Council Of The University Of Toronto | Immunological materials |
| CH621479A5 (cg-RX-API-DMAC7.html) * | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
| IT1110989B (it) * | 1979-01-19 | 1986-01-13 | Erba Farmitalia | Forme farmaceutiche costitutite da liposomi e procedimenti relativi |
| FR2416008A1 (fr) * | 1978-02-02 | 1979-08-31 | Oreal | Lyophilisats de liposomes |
| GB1575344A (en) * | 1978-03-03 | 1980-09-17 | Ici Ltd | Method for the manufacture of liposome composition |
| HU184141B (en) * | 1979-12-27 | 1984-07-30 | Human Oltoanyagtermelo | Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof |
-
1982
- 1982-02-17 FR FR8202620A patent/FR2521565B1/fr not_active Expired
-
1983
- 1983-02-07 CA CA000421067A patent/CA1208133A/en not_active Expired
- 1983-02-09 DE DE8383400281T patent/DE3364299D1/de not_active Expired
- 1983-02-09 AT AT83400281T patent/ATE20574T1/de active
- 1983-02-09 DE DE198383400281T patent/DE87993T1/de active Pending
- 1983-02-09 EP EP83400281A patent/EP0087993B2/fr not_active Expired - Lifetime
- 1983-02-10 US US06/465,598 patent/US4508703A/en not_active Expired - Lifetime
- 1983-02-15 GR GR70504A patent/GR77128B/el unknown
- 1983-02-16 DK DK67783A patent/DK67783A/da not_active Application Discontinuation
- 1983-02-17 IL IL67939A patent/IL67939A0/xx unknown
- 1983-02-17 ES ES519878A patent/ES519878A0/es active Granted
- 1983-02-17 JP JP58025447A patent/JPS5931707A/ja active Granted
-
1987
- 1987-06-29 SG SG558/87A patent/SG55887G/en unknown
- 1987-11-19 HK HK852/87A patent/HK85287A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES8404690A1 (es) | 1984-05-01 |
| HK85287A (en) | 1987-11-27 |
| ATE20574T1 (de) | 1986-07-15 |
| EP0087993B1 (fr) | 1986-07-02 |
| EP0087993B2 (fr) | 1990-01-03 |
| SG55887G (en) | 1987-11-13 |
| DK67783D0 (da) | 1983-02-16 |
| FR2521565B1 (fr) | 1985-07-05 |
| FR2521565A1 (fr) | 1983-08-19 |
| DE87993T1 (de) | 1984-02-16 |
| GR77128B (cg-RX-API-DMAC7.html) | 1984-09-07 |
| JPH0150449B2 (cg-RX-API-DMAC7.html) | 1989-10-30 |
| ES519878A0 (es) | 1984-05-01 |
| DE3364299D1 (en) | 1986-08-07 |
| IL67939A0 (en) | 1983-06-15 |
| JPS5931707A (ja) | 1984-02-20 |
| DK67783A (da) | 1983-08-18 |
| US4508703A (en) | 1985-04-02 |
| EP0087993A1 (fr) | 1983-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1208133A (en) | Pulverulent mixture of lipidic constituents and hydrop hobic constituents, methods for obtaining the same hyd rated lipidic lamellar phases and method for producing the same, pharmaceutical or cosmetic compositions com prising hydrated lipidic lamellar phases | |
| DE3713493C3 (de) | Kosmetisches oder pharmazeutisches Mittel auf Basis einer wäßrigen Dispersion von Lipidkügelchen | |
| US4897308A (en) | Compositions comprising aqueous dispersions of lipid spheres | |
| US4217344A (en) | Compositions containing aqueous dispersions of lipid spheres | |
| US4772471A (en) | Aqueous dispersions of lipid spheres and compositions containing the same | |
| US5171577A (en) | Process for the preparation of foams which can be used in the cosmetics and pharmaceutical field and foams obtained by this process | |
| EP1183008B1 (en) | Aqueous carrier systems for lipophilic ingredients | |
| JPH0131414B2 (cg-RX-API-DMAC7.html) | ||
| JPS588287B2 (ja) | 脂質小球の水性分散液の製法 | |
| DE3713494A1 (de) | Verfahren zur herstellung einer dispersion von lipidkuegelchen in einer waessrigen phase und nach diesem verfahren erhaeltliche dispersionen | |
| DE3713492C2 (cg-RX-API-DMAC7.html) | ||
| EP0629128B1 (en) | Aqueous phospholipid vesicle dispersion, process for its manufacture and use thereof | |
| JP7384518B2 (ja) | 難溶性成分安定化用組成物及びそれを含む化粧料組成物 | |
| JP2009120584A (ja) | 連続水相と分散脂肪相とを含むエマルジョンの形態の化粧品組成物、及びその調製方法 | |
| JP2006131567A (ja) | リポソーム懸濁液の製造方法及びリポソームを用いた用途 | |
| HUT77012A (hu) | Kaolintartalmú kozmetikai készítmény | |
| JP4049216B2 (ja) | 液晶構造を有する製剤 | |
| EP0713380B1 (de) | Funktionelles sauerstoffhaltiges präparat enthaltend phospholipide und fluorcarbon | |
| JPH06321772A (ja) | 水性リポソーム系およびそのリポソーム系の調製法 | |
| CN118453444A (zh) | 高稳定性复合物及其制备方法、日用品和药品 | |
| JPH06279467A (ja) | リン脂質組成物 | |
| EP0759736B1 (en) | Liposome forming compositions | |
| KR102632679B1 (ko) | 히알루론산 봉입 나노 입자 전달체 및 이의 제조방법 | |
| KR20070101426A (ko) | 에스터화 레시딘을 이용한 나노리포좀 | |
| NL8102794A (nl) | Werkwijze voor het bereiden van een dispersie van kleine bolvormige deeltjes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry | ||
| MKEX | Expiry |
Effective date: 20030722 |